AstraZeneca spearheads lung cancer alliance aiming to boost survival rates

AstraZeneca wants to double the five-year lung cancer survival rate by 2025. That’s an ambitious target for a disease that's the leading cause of cancer deaths in the U.S. But AZ isn't planning to do it alone. It's one of four founding partners of the new Lung Ambition Alliance that seeks to do in lung cancer what has happened in breast cancer⁠—that is, spur an ecosystem of awareness, screening, early diagnosis, support and innovative research and treatments to ramp up survival rates.